BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival

Overview of attention for article published in Clinical Cancer Research, October 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 1 X user

patent: 12 patents

Readers on

mendeley: 55 Mendeley

So far, Altmetric has seen 12 patents that reference this research output.

Small molecule inhibitors of BCL-2-associated death promoter (BAD) phosphorylation

Grant US-11292773-B2

United States of America

05 Apr 2022

Six-gene biomarker of survival and response to platinum based chemotherapy in serious…

Grant US-10167516-B2

United States of America

01 Jan 2019

Method of diagnosing, treating and determining progression and survival of cancer cells…

Grant US-9983209-B2

United States of America

29 May 2018

O-glycan pathway ovarian cancer signature

Grant US-9809858-B2

United States of America

07 Nov 2017

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 8 additional patents.